Revive Therapeutics Provides Update on Phase 3 Clinical ... - InvestorsHub
https://ih.advfn.com/stock-market/USOTC/revive-therapeutics-qb-RVVTF/stock-news/87272569/revive-therapeutics-provides-update-on-phase-3-cli
WebFeb 14, 2022 · Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19. TORONTO, Feb. 14, 2022 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and …
DA: 3 PA: 33 MOZ Rank: 70